The Medicines Co (MDCO)

40.10
0.13 0.31
NASDAQ : Health Care
Prev Close 40.23
Open 40.09
Day Low/High 39.59 / 40.80
52 Wk Low/High 27.50 / 43.79
Volume 372.78K
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 70.56M
Market Cap 2.81B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

The Medicines Company announced that the U.S.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Medicines (MDCO) Flagged As Strong On High Volume

Medicines (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company (NASDAQ:MDCO) today announced that its investigational antibiotic, CARBAVANCE ® (meropenem-vaborbactam), met both FDA and EMA pre-specified primary endpoints in the Phase 3 TANGO 1 clinical trial...

The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi

The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi

The Medicines Company (NASDAQ:MDCO) today announced the completion of the previously-disclosed divestiture of its non-core cardiovascular assets, Cleviprex® (clevidipine) injectable emulsion, Kengreal® (cangrelor)...

Insiders Are Scooping Up Shares of These 5 Stocks

Insiders Are Scooping Up Shares of These 5 Stocks

Here's a technical look at how to trade five stocks that have seen recent insider buying.

The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700

The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700

The Medicines Company announced today that it has dosed the first patient in a Phase II study of ABP-700 in procedural sedation.

The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston

The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston

The Medicines Company (NASDAQ:MDCO) today announced that 11 presentations on its infectious disease programs will be presented at the first annual ASM Microbe 2016 to be held June 16-20 in Boston, MA.

MDCO: Insiders vs. Shorts

MDCO: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 13.02 "days to cover" versus the median component at 5.75. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Medicines (MDCO) as a pre-market mover with heavy volume candidate

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors.

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the ORION-1 study of PCSK9si, its investigational first-in-class RNA interference (RNAi) proprotein convertase subtilisin/kexin type...

The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)

The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE® (meropenem-vaborbactam), an investigational agent being developed for the treatment of...

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences: Jefferies 2016 Healthcare Conference - New York City, Tuesday,...

5 Stocks Insiders Are Scooping Up Right Now

5 Stocks Insiders Are Scooping Up Right Now

Insiders at these five companies have been buying shares of their own stock recently. Should you?

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer.

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first quarter ended March 31, 2016.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a definitive agreement to sell Cleviprex® (clevidipine), Kengreal® (cangrelor) and the Company's rights to Argatroban for Injection to...

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016, at 8:00 AM PT (11:00 AM ET).

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for May 9 th at 8:30 a.

FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)

FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)

The Medicines Company (NASDAQ:MDCO) today announced that the U.S.

The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam

The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam

The Medicines Company (NASDAQ:MDCO) today announced that investigators will present data for the Phase 3 investigational agent CARBAVANCE® (meropenem-vaborbactam) on activity against newly discovered BKC-1...

The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago

The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago

The Medicines Company (NASDAQ:MDCO) today announced that investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with its...

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Stocks with insider trader activity include MDCO, DXCM and WMGI

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Wednesday, March 9, 2016, at 8:40 AM EST.

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the 2016 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, February 23 rd at 8:00am EST.